H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a price target of $60.00. Patrick Trucchio’s rating is based on ...

Precision BioSciences’ most advanced cell therapy for a type of blood cancer is on track for a pivotal clinical trial, but that study is no longer its responsibility.

Precision Biosciences (NASDAQ:DTIL) is a biotech company with a proprietary gene-editing platform - ARCUS - 15 years in the making, and a promising genome editing endonuclease ...

Precision BioSciences is also currently evaluating PBGENE-PMM, a first-of-its-kind treatment for m.3243 associated mitochondrial disease, in pre-clinical studies.

Precision BioSciences, a clinical stage gene editing company, today announced promotions and organizational changes that impact responsibilities within the company’s senior leadership team.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies w ...

DURHAM – Precision BioSciences, a genome-editing company based in Durham, announced today the opening of its highly prized production facility for in-house manufacturing of its unique technologies.

Precision BioSciences is slated to present a poster at the 64th ASH Annual Meeting between December 10th and 13th. See why DTIL stock is a Buy.

DURHAM, N.C., July 06, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS ...

- PBGENE-HBV is the first in vivo gene editing program for chronic hepatitis B virus to move into global clinical trials - Company to host investor event highlighting clinical candidate safety ...

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform.

Precision BioSciences will be entitled to receive an upfront payment of $75 million from NVS. The company is also eligible to receive up to an additional $1.4 billion as future milestone ...